Vor Biopharma (NASDAQ:VOR) Earns Buy Rating from Analysts at Citigroup

Citigroup initiated coverage on shares of Vor Biopharma (NASDAQ:VOR) in a report issued on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $50.00 price objective on the stock.

A number of other equities research analysts have also issued reports on the stock. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Wednesday, September 24th. Wedbush started coverage on Vor Biopharma in a research note on Tuesday, November 25th. They set a “neutral” rating on the stock. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Robert W. Baird upgraded Vor Biopharma from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $20.00 to $64.00 in a research report on Wednesday, October 15th. Finally, HC Wainwright dropped their price target on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vor Biopharma presently has an average rating of “Moderate Buy” and an average target price of $66.13.

Vor Biopharma Stock Up 5.8%

VOR opened at $13.52 on Friday. Vor Biopharma has a 12-month low of $2.62 and a 12-month high of $65.80. The firm has a market capitalization of $140.74 million, a PE ratio of -0.03 and a beta of 2.02. The company has a fifty day moving average of $12.04.

Insiders Place Their Bets

In other news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $30.05, for a total transaction of $349,060.80. Following the completion of the transaction, the insider owned 1,167,109 shares of the company’s stock, valued at approximately $35,071,625.45. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. sold 24,579 shares of the company’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $25.12, for a total transaction of $617,424.48. Following the transaction, the director owned 779,652 shares of the company’s stock, valued at $19,584,858.24. This represents a 3.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 1,347,526 shares of company stock worth $38,216,989 over the last quarter. 0.45% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Vor Biopharma

Several large investors have recently made changes to their positions in the company. Ariose Capital Management Ltd acquired a new stake in Vor Biopharma in the 3rd quarter valued at approximately $5,368,000. Goldman Sachs Group Inc. boosted its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares during the period. Woodline Partners LP bought a new position in shares of Vor Biopharma in the third quarter worth $1,333,000. Millennium Management LLC grew its stake in shares of Vor Biopharma by 122.5% in the third quarter. Millennium Management LLC now owns 24,764 shares of the company’s stock worth $1,207,000 after purchasing an additional 134,764 shares in the last quarter. Finally, Polymer Capital Management HK LTD acquired a new position in shares of Vor Biopharma during the third quarter valued at $1,035,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).